P Raskin

Summary

Publications

  1. ncbi request reprint Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone
    P Raskin
    University of Texas, South Western Medical Center, Dallas, TX, USA
    Diabet Med 21:329-35. 2004
  2. doi request reprint Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:947-52. 2009
  3. ncbi request reprint Weight gain in type 2 diabetes mellitus
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center in Dallas, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 9:386-93. 2007
  4. doi request reprint Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:865-73. 2009
  5. doi request reprint Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
    P Raskin
    Department of Internal Medicine, Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 10:1167-77. 2008
  6. ncbi request reprint Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Diabetes Obes Metab 11:27-32. 2009
  7. ncbi request reprint A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Diabetes Care 24:1226-32. 2001
  8. ncbi request reprint Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    P Raskin
    Southwestern Medical Center at Dallas, University of Texas, 75390 8858, USA
    Diabetes Care 23:583-8. 2000
  9. ncbi request reprint A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, G5-238, Dallas, TX 75390-8858, USA
    J Diabetes Complications 15:295-300. 2001
  10. pmc Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 31:2177-82. 2008

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone
    P Raskin
    University of Texas, South Western Medical Center, Dallas, TX, USA
    Diabet Med 21:329-35. 2004
    ....
  2. doi request reprint Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:947-52. 2009
    ..To assess the efficacy and safety of a new repaglinide/metformin fixed-dose combination (FDC) tablet administered either twice a day (BID) or three times a day (TID) for the management of type 2 diabetes...
  3. ncbi request reprint Weight gain in type 2 diabetes mellitus
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center in Dallas, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 9:386-93. 2007
    ..To investigate the potential causes of weight gain using insulin and combination therapy in type 2 diabetes...
  4. doi request reprint Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:865-73. 2009
    ..To assess the use of a new repaglinide/metformin fixed-dose combination (FDC) tablet for the treatment of type 2 diabetes...
  5. doi request reprint Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
    P Raskin
    Department of Internal Medicine, Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 10:1167-77. 2008
    ..The combination regimen of repaglinide plus metformin should therefore be considered as a valuable option in the management of patients with type 2 diabetes when monotherapy is no longer adequate...
  6. ncbi request reprint Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Diabetes Obes Metab 11:27-32. 2009
    ....
  7. ncbi request reprint A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Diabetes Care 24:1226-32. 2001
    ..To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy...
  8. ncbi request reprint Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    P Raskin
    Southwestern Medical Center at Dallas, University of Texas, 75390 8858, USA
    Diabetes Care 23:583-8. 2000
    ..The improvement was not obtained at an increased risk of hypoglycemia. HbA1c was slightly, but significantly, lower for IAsp compared with HI at 6 and 12 months...
  9. ncbi request reprint A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, G5-238, Dallas, TX 75390-8858, USA
    J Diabetes Complications 15:295-300. 2001
    ..When used in external pumps, insulin lispro provides better glycemic control than buffered regular human insulin with a similar adverse event profile...
  10. pmc Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 31:2177-82. 2008
    ....
  11. ncbi request reprint Idiopathic Type 1 diabetes
    A Piñero-Piloña
    Department of Internal Medicine, University of Texas Southwestern Medical School, G4 100, 5323 Harry Hines Boulevard, Dallas, TX 75390 8858, USA
    J Diabetes Complications 15:328-35. 2001
    ..Although the pathogenesis of this disease is unknown, it may be related to lipotoxicity, glucose toxicity or transcription factors involved in fuel metabolism...
  12. ncbi request reprint Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience
    A Piñero-Piloña
    Department of Internal Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    Diabetes Care 24:1014-8. 2001
    ....
  13. doi request reprint Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Diabetes Obes Metab 14:163-73. 2012
    ..This study evaluated pulmonary function changes in diabetes patients receiving inhaled Technosphere Insulin (TI) or usual antidiabetes treatment (usual care)...
  14. ncbi request reprint The visceral and subcutaneous fat changes in type 1 diabetes: a pilot study
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 8:524-30. 2006
    ..To evaluate the effects of improved glycaemic control on the abdominal visceral and subcutaneous fat in type 1 diabetes...
  15. doi request reprint Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine
    A C Moses
    Novo Nordisk Inc, Princeton, NJ, USA
    Diabet Med 25:200-5. 2008
    ....
  16. ncbi request reprint Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
    V Fonseca
    Tulane University, New Orleans, LA 70112, USA
    Diabet Med 24:759-63. 2007
    ..To determine whether the beneficial effects of carvedilol on insulin resistance (IR) are affected by the concomitant use of insulin sensitizers [thiazolidinediones (TZDs) and metformin]...
  17. ncbi request reprint Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US
    J A Ray
    CORE Center for Outcomes Research, A Unit of IMS, Binningen Basel, Switzerland
    Diabetes Obes Metab 9:103-13. 2007
    ..insulin glargine in insulin-naïve type 2 diabetes patients failing to achieve glycemic control with oral antidiabetic agents alone (OADs)...
  18. ncbi request reprint beta-blocker use and diabetes symptom score: results from the GEMINI study
    J B McGill
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Diabetes Obes Metab 9:408-17. 2007
    ..In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms...
  19. ncbi request reprint Potential causes of weight gain in type 1 diabetes mellitus
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center in Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 8:404-11. 2006
    ..To investigate the potential causes of weight gain with insulin therapy and improved diabetic control in type 1 diabetes mellitus...
  20. ncbi request reprint A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients
    D Lender
    Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, USA
    Am J Hypertens 12:298-303. 1999
    ..3 mg/dL, P = .004). Amlodipine and enalapril were associated with increments in insulin sensitivity. Amlodipine provided an additional benefit with decreased low density lipoprotein cholesterol levels...
  21. ncbi request reprint Relationship between insulin sensitivity, hyperinsulinemia, and insulin-mediated sympathetic activation in normotensive and hypertensive subjects
    C Arauz-Pacheco
    Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, 75235-8858, USA
    Am J Hypertens 9:1172-8. 1996
    ..The greater degree of sympathetic activation observed in hypertensive subjects is a function of the level of insulinemia obtained during the clamps...